By applying the marker panel (ZNF582, ASCL1 and SST) previously designed for AIN3+ detection in HIV+ MSM at the non‐CV J‐threshold,[11] we found that this panel classified a similar proportion of samples of HIV‐negative women and men as methylation‐positive: 98% (39/40) of the cancers, 64% (18/28) of AIN3, 62% (13/21) of AIN2, 11% (6/57) of AIN1 and 17% (5/30) of normal control samples. This evidence concerns the gene ZNF582 and cancer.